|
Home History of Buteyko How Does Buteyko Work? Buteyko Courses Research, Resources & Links |
Buteyko Institute Method Clinical Trials International update Award-winning Researcher: Jean McGowan, Nursing Lecturer, Nurse Consultant Presented at the 2nd International Buteyko Conference, Melbourne Australia, July 27, 2002. Pilot Study April 2000 100 participants` two groups -- 50 active --50 control Purpose of a pilot study is to enable the researcher to test and try the methodology, questionnaires and relevant documents. Any identified difficulties can be altered or adapted; this measure is taken to ensure that the study gleans the most significant information in an objective and unbiased manner. Follow - up was over a 12 month period with final report at the 12 months from commencement. Outcomes measured Primary Objective Asthma Symptoms, Secondary Objective Blood Pressure, QOL, SF 36 Questionnaire. Limitations Identified Lack of blinding, Flawed methodology, No Testing of BIM, Comparison of 2 methods of Management. April 2001 ----- Clinical Trial The study consisted of three distinct groups Group 1: Taught the Buteyko Method, by Senior Practitioner Group 2: Taught Conventional Asthma Health Education by Nurse Group 3: Intervention on demand only All participants had been given basic information / education on asthma management, compliance with medication, diet, exercise and peak flow recordings. All three groups completed SF36 questionnaire at - pre, post and six monthly intervals over a twenty four month period. Interim report scheduled at 12 month from commencement. Both groups - who had not been included - are offered the opportunity to undertake the BIM at this point. This is done by written invitation and scheduled into arranged clinics at the sites already identified for the study. Comparisons to be made at this point are 1 ---- Medication costs (pre and pos ) BIM, including projected savings to NHS / GP Practice 2 ---- Asthma Symptoms 3 ---- Blood Pressure 4 ---- QOL Method is delivered as Health Education Programme Benefits First year results of Buteyko Institute Method clinical trial in Glasgow Trial commenced 30 April 2001 Researcher: Jean McGowan, 2 May 2002 Daily activities Buteyko Group - increased by 60%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Physical Exercise - Sports Activity Buteyko Group - increased by 95%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Asthma Symptoms Buteyko Group - decreased by 98%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Reliever Medication Buteyko Group - decreased by 98%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Preventer Medication Buteyko Group - decreased by 92%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Reliever Oral Preparations Buteyko Group - decreased by 100%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Preventer Oral Preparations Buteyko Group - decreased by 96%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Instance of cold or viral infection Buteyko Group - decreased by 20%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Vitality Buteyko Group - increased by 80%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Quality of Life Buteyko Group - increased by 100%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Social and Recreational Buteyko Group - increased by 60%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Emotional Buteyko Group - increased by 100%, 6 months and remained same at 12 months Placebo and Control groups - no significant change Mental Health Buteyko, Placebo and Control groups - no significant change Secondary Objective - Blood Pressure (BP) Buteyko Group - 75% had a reduction in BP, bringing it back into normal limits, and a corresponding reduction in heart rate, was evident at 6 months and sustained same at 12 months Placebo and Control groups - no significant change Back to Research, Resources & Links. back to top |
Test Your Breathing Who Can Buteyko Help? Client Testimonials FAQs Buteyko Institute |
